Literature DB >> 27098116

CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment.

Artjoms Spaks1, Darja Svirina2, Irina Spaka3, Inta Jaunalksne4, Donats Breiva1, Ilmars Tracums1, Dainis Krievins5,6.   

Abstract

OBJECTIVE: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes. PATIENTS AND METHODS: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count.
RESULTS: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival.
CONCLUSIONS: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.

Entities:  

Keywords:  Angiogenesis; CXC chemokine ligand 4; chemokines; non-small cell lung cancer; platelet factor 4

Mesh:

Substances:

Year:  2016        PMID: 27098116     DOI: 10.3109/1354750X.2016.1172111

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  10 in total

1.  The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma.

Authors:  Ricardo J Flores; Aaron J Kelly; Yiting Li; Xiang Chen; Colin McGee; Mark Krailo; Donald A Barkauskas; John Hicks; Tsz-Kwong Man
Journal:  Pediatr Blood Cancer       Date:  2017-05-24       Impact factor: 3.167

2.  Role of CXC group chemokines in lung cancer development and progression.

Authors:  Artjoms Spaks
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

3.  CXCL5 regulation of proliferation and migration in human non-small cell lung cancer cells.

Authors:  Lin Wang; Lin Shi; Jie Gu; Cheng Zhan; Junjie Xi; Jianyong Ding; Di Ge
Journal:  J Physiol Biochem       Date:  2018-03-10       Impact factor: 4.158

4.  A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among CC and CXC chemokines in breast cancer.

Authors:  Hossein Hozhabri; Marziyeh Mazaheri Moghaddam; Madiheh Mazaheri Moghaddam; Ali Mohammadian
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

Review 5.  What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist.

Authors:  Sassine Ghanem; Sandy El Bitar; Sami Hossri; Chanudi Weerasinghe; Jean Paul Atallah
Journal:  Cancer Manag Res       Date:  2017-07-06       Impact factor: 3.989

6.  Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.

Authors:  Fei Feng; Bin Wang; Xiuxuan Sun; Yumeng Zhu; Hao Tang; Gang Nan; Lijuan Wang; Bo Wu; Muren Huhe; Shuangshuang Liu; Tengyue Diao; Rong Hou; Yang Zhang; Zheng Zhang
Journal:  Cancer Biol Ther       Date:  2017-01-02       Impact factor: 4.742

7.  Prognostic Significance and Therapeutic Target of CXC Chemokines in the Microenvironment of Lung Adenocarcinoma.

Authors:  Kun Wang; Rongyang Li; Yu Zhang; Weifeng Qi; Tao Fang; Weiming Yue; Hui Tian
Journal:  Int J Gen Med       Date:  2022-02-28

8.  Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.

Authors:  Yixiang Huang; Wei Jian; Junyong Zhao; Gang Wang
Journal:  Onco Targets Ther       Date:  2018-04-17       Impact factor: 4.147

9.  Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.

Authors:  Zhiwei Sun; Shixia Zhou; Junling Tang; Ting Ye; Jingyuan Li; Doudou Liu; Jian Zhou; Jianyu Wang; H Rosie Xing
Journal:  EBioMedicine       Date:  2018-10-06       Impact factor: 8.143

10.  Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer.

Authors:  Kaisheng Liu; Minshan Lai; Shaoxiang Wang; Kai Zheng; Shouxia Xie; Xiao Wang
Journal:  Biomed Res Int       Date:  2020-03-30       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.